Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

Results Show Improvements in RA Signs and Symptoms Compared to Placebo

SEATTLE, Sept. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced preliminary analysis of results from a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial of its TRU-015 product candidate for rheumatoid arthritis (RA). The results indicated that Trubion's TRU-015 product candidate, at well-tolerated dosages, provided statistically significant improvements in RA signs and symptoms compared to placebo at 24 weeks. Trubion is co-developing TRU-015 with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), for the treatment of rheumatoid arthritis.

TRU-015 Phase IIb Clinical Trial Protocol and Results

The Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial included 276 patients with rheumatoid arthritis who were also receiving methotrexate as background therapy. Patients in the Phase IIb study were randomized evenly into five groups that received either placebo, 200 mg, 400 mg, 800 mg or 1600 mg of TRU-015.

The study was designed to evaluate the safety and efficacy of a single intravenous infusion of TRU-015 compared to placebo for a 24-week period, with a primary endpoint of improvement on the Disease Activity Score (DAS)-28 scale at 12 weeks, and secondary endpoints including response rates at 24 weeks using American College of Rheumatology (ACR) criteria.

Preliminary analysis i
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans ... OxyContin is a serious public health and safety issue in ... from a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication ... progress with this very serious health situation facing our country," ...
(Date:8/21/2014)... Aug. 21, 2014  Henry Schein, Inc. (NASDAQ: ... and services to office-based dental, animal health and medical practitioners, ... conferences in September: , September 4, 2014 – ... , NY at 12:50 p.m. ET , September 8, 2014 ... New York , NY at 1:25 p.m. ET ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3Henry Schein To Present At Two Investor Conferences In September 2
... 4, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. ... "Company"), an emerging leader in the development, assembly, marketing ... in China, today announced that it will release financial ... June 30, 2011 on Monday, August 15, 2011 before ...
... Medical, Inc. (OTCBB: HASC), www.mysouthernmed.com , a ... Florida, and Mississippi, announced today that the Chairman ... guaranteed the financing that was used for the ... on May 17th, 2011. As part ...
Cached Medicine Technology:Dehaier Medical to Report Second Quarter 2011 Financial Results on August 15 2HASCO Medical Chairman Provides $2 Million in Capital and a Personal Guarantee on Additional $2 Million Promissory Note 2HASCO Medical Chairman Provides $2 Million in Capital and a Personal Guarantee on Additional $2 Million Promissory Note 3
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 Sleep Apnea ... across the U.S. This provides doctors with a convenient way ... find a doctor are that much closer to finding ... have no idea they are experiencing this sleep disorder ... receive treatment at all. , Thanks to Sleep Apnea Doctors ...
(Date:8/21/2014)... Cary, NC (PRWEB) August 21, 2014 ... solutions for the health and human services markets, announced ... features and capabilities incorporating the Tin Can API. ... and their employees have the most advanced mobile learning ... greatest in adult learning tools and techniques,” says Jim ...
(Date:8/21/2014)... ERT, a leading global solution ... endpoint data collection, today opened registration for ... Product Value with Optimized Endpoints. The ... developers to network with leading researchers as ... implementing, and justifying effective strategies for collecting ...
(Date:8/21/2014)... elicited by T-type calcium channels in the thalamic ... of calcium. These channels enable thalamic reticular nucleus ... to enter a hyper-excited state. , In order ... absence seizures, the researchers conducted an experiment to ... techniques to delete the T-type calcium channel CaV3.3. ...
(Date:8/21/2014)... Do we drive to work or take the train? From ... make hundreds of different decisions every day. Even if these ... for our long-term personal development to make decisions that are ... difficult, however. They are known to make impulsive decisions, often ... of making a choice that yields a greater reward later ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea Doctors US is Now Offering Complimentary Listings to Sleep Apnea Doctors Across the United States 2Health News:Relias Learning Announces Support for Tin Can API 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:ADHD children make poor decisions due to less differentiated learning processes 2
... SOUTH SAN FRANCISCO, Calif., July 29 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman ... overview, including a discussion about the clinical development program for ... conferences: , , , ...
... , SAN DIEGO, July 29, 2009 Arena ... will report second quarter 2009 financial results after the NASDAQ ... afternoon, Jack Lief, Arena,s President and Chief Executive Officer, and ... Officer, will host a conference call at 5:00 p.m. Eastern ...
... , JACKSONVILLE, Fla., July 29 Today, Wounded ... bill (H.R. 3155) that will assist the family caregivers of ... (S. 801) that would provide more comprehensive support and coverage ... need of these services. H.R. 3155, the Caregiver Assistance and ...
... SAN FRANCISCO, July 29 Medivation, Inc. (Nasdaq: ... and webcast with management to discuss second quarter 2009 financial results ... at 4:30 p.m. Eastern Time. A press release for the second ... on August 5, 2009. , , Interested parties ...
... , , , , ... Carefx Corporation , a leading provider of interoperable workflow ... that one of its clients, the Louisiana Rural Health Information Exchange (LARHIX), ... Health Information Executives , a top healthcare information technology magazine. ...
... , , MONROVIA, ... ), a leading developer, manufacturer and marketer of minimally invasive ophthalmic ... Officer will present at the BMO Capital Markets 9th Annual Focus ... 5th at 4:00 pm Eastern Time. , , ...
Cached Medicine News:Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2Health News:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009 2Health News:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009 3Health News:Wounded Warrior Project (WWP) Pushes for Senate Bill to Assist Family Caregivers of the Most Severely Injured Veterans 2Health News:Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009 2Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 2Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 3
... to U.S. and international engineering and ... Screw and Plating System* provides seamless ... of use for open reduction internal ... TC-100 system works well beyond the ...
... The Alphatec Small Fragment ... wide range of fractures, including ... distal humerus, distal radius, distal ... malleolus, metatarsals, and metacarpals. The ...
Stainless steel threaded Steinman Pins available in point types A,D, E, and F....
Round Bevel-Point Pin Sets available in 2.3mm, 3.1mm, 4.7mm, and 6.3mm sizes....
Medicine Products: